JP2018509394A5 - - Google Patents

Download PDF

Info

Publication number
JP2018509394A5
JP2018509394A5 JP2017541594A JP2017541594A JP2018509394A5 JP 2018509394 A5 JP2018509394 A5 JP 2018509394A5 JP 2017541594 A JP2017541594 A JP 2017541594A JP 2017541594 A JP2017541594 A JP 2017541594A JP 2018509394 A5 JP2018509394 A5 JP 2018509394A5
Authority
JP
Japan
Prior art keywords
polypeptide
dimer
group
terminus
terminal extension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017541594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509394A (ja
JP6894375B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/052578 external-priority patent/WO2016124781A1/en
Publication of JP2018509394A publication Critical patent/JP2018509394A/ja
Publication of JP2018509394A5 publication Critical patent/JP2018509394A5/ja
Application granted granted Critical
Publication of JP6894375B2 publication Critical patent/JP6894375B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017541594A 2015-02-05 2016-02-05 C末端で操作されたシステインを介して連結されたNanobodyダイマー Active JP6894375B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562112218P 2015-02-05 2015-02-05
US62/112,218 2015-02-05
US201562269434P 2015-12-18 2015-12-18
US62/269,434 2015-12-18
PCT/EP2016/052578 WO2016124781A1 (en) 2015-02-05 2016-02-05 Nanobody dimers linked via c-terminally engineered cysteins

Publications (3)

Publication Number Publication Date
JP2018509394A JP2018509394A (ja) 2018-04-05
JP2018509394A5 true JP2018509394A5 (enExample) 2019-03-22
JP6894375B2 JP6894375B2 (ja) 2021-06-30

Family

ID=55315425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017541594A Active JP6894375B2 (ja) 2015-02-05 2016-02-05 C末端で操作されたシステインを介して連結されたNanobodyダイマー

Country Status (8)

Country Link
US (1) US11021544B2 (enExample)
EP (1) EP3262068A1 (enExample)
JP (1) JP6894375B2 (enExample)
CN (1) CN107667113B (enExample)
AU (2) AU2016214317B2 (enExample)
CA (1) CA2975810C (enExample)
HK (1) HK1249528A1 (enExample)
WO (1) WO2016124781A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2772348T3 (es) * 2014-12-19 2020-07-07 Ablynx Nv Dímeros de Nanobody con uniones cisteína
KR20250011229A (ko) 2017-06-02 2025-01-21 메르크 파텐트 게엠베하 Adamts 결합성 면역글로불린
CN108610415B (zh) * 2018-05-15 2025-08-29 康元大工生物技术(大连)有限公司 一种抗体复合物的制备方法
JP7603600B2 (ja) * 2019-03-08 2024-12-20 リンクシス ベスローテン フェンノートシャップ 細胞増殖又は細胞分化に関与する受容体を標的にする内在化結合分子
EP3792283A1 (en) * 2019-09-16 2021-03-17 Lava Therapeutics B.V. Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
CN111004328A (zh) * 2019-12-11 2020-04-14 深圳市国创纳米抗体技术有限公司 一种用于双抗体夹心法检测癌胚抗原的纳米抗体组合
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
CA3175873A1 (en) * 2020-03-30 2021-10-07 Ablynx Nv Method for the production and purification of multivalent immunoglobulin single variable domains
EP4214235A1 (en) * 2020-09-16 2023-07-26 LinXis B.V. Internalizing binding molecules
CN114957476A (zh) * 2021-02-23 2022-08-30 复旦大学 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体
CN113624898B (zh) * 2021-08-23 2023-08-25 成都诺和晟泰生物科技有限公司 一种手性镇痛类多肽药物的纯化方法
EP4463135A2 (en) * 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
CN114957478B (zh) * 2022-05-30 2023-08-18 华南农业大学 一种抗肉桂酰胺类杀菌剂的纳米抗体及其应用
WO2024238790A1 (en) 2023-05-17 2024-11-21 Odyssey Therapeutics, Inc. Modified single-domain antibodies
WO2024243469A1 (en) * 2023-05-23 2024-11-28 The University Of Chicago Delivery of dna binding and transcriptional regulation compositions
EP4556907A1 (en) 2023-11-20 2025-05-21 Miltenyi Biotec B.V. & Co. KG Site-specific conjugation of single domain antibody fragments (vhh) using equilibrium transfer alkylation reagent (etac)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2492092A1 (en) * 2002-06-28 2004-01-08 Greg Winter Immunoglobin single variant antigen-binding domains and dual-specific constructs
US9701754B1 (en) * 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US7958832B2 (en) * 2008-08-29 2011-06-14 Nike, Inc. Awl for making an awl feature in material for apparel
DK2982690T3 (da) * 2009-04-30 2021-04-12 Ablynx Nv Fremgangsmåde til fremstilling af domæne-antistoffer
US9150640B2 (en) * 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
US8987417B2 (en) * 2010-11-29 2015-03-24 National Research Council Of Canada Covalently dimerized bivalent binding agents
LT2771364T (lt) 2011-10-27 2019-09-10 Genmab A/S Heterodimerinių baltymų gamyba
JP2015521615A (ja) * 2012-06-19 2015-07-30 ポリセリックス・リミテッド 抗体コンジュゲートの調製のための新規方法及び新規抗体コンジュゲート
CN105814082A (zh) * 2013-09-26 2016-07-27 埃博灵克斯股份有限公司 双特异性纳米抗体
ES2772348T3 (es) * 2014-12-19 2020-07-07 Ablynx Nv Dímeros de Nanobody con uniones cisteína

Similar Documents

Publication Publication Date Title
JP2018509394A5 (enExample)
US20250161479A1 (en) Transglutaminase conjugation method and linker
CN112261954B (zh) 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
US10941145B2 (en) Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
CA2917544C (fr) Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
EP2968583B1 (en) Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
JP2018510864A (ja) トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体
EP3668869A1 (en) 6-amino-7,9-dihydro-8h-purin-8-one derivatives as toll-like receptor 7 (tlr7) agonists as immunostimulants
JP2020531466A (ja) 免疫刺激物質トル様受容体7(tlr7)アゴニストとしての6−アミノ−7,9−ジヒドロ−8h−プリン−8−オン誘導体
JP2020531469A (ja) 三環式基を有するトル様受容体7(tlr7)アゴニスト、そのコンジュゲート、ならびにそれらの方法および使用
JP2017537893A5 (enExample)
EP3102606A2 (en) Antibody-drug conjugates and immunotoxins
JP2020506685A5 (enExample)
KR101972012B1 (ko) 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도
JP2018509908A5 (enExample)
EP3102244A2 (en) Antibody-drug conjugates and immunotoxins
JP2016539190A5 (enExample)
KR20210102334A (ko) 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도
CA3222359A1 (en) Conjugates of checkpoint inhibitors with il-2, and uses thereof
KR102861586B1 (ko) 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도
WO2019191630A1 (en) Selective reduction of antibodies
WO2020096775A1 (en) Sulfatase-cleavable linkers for antibody-drug conjugates
EA045916B1 (ru) Антитело, содержащее глутаминсодержащее с-концевое удлинение легкой цепи, его конъюгаты, способы и пути применения